Loading...

MedXY News - clinical trials

MedXY AI/MedXY News/Tag: clinical trials

MedXY News

EnglishTag

clinical trials

84 all articles · 20 / page

Ask MedXY AI

clinical trial type 2 diabetes heart failure immunotherapy obesity atrial fibrillation Cardiology oncology cardiovascular risk biomarkers clinical trials public health Hypertension critical care breast cancer artificial intelligence Alzheimer's disease diabetes nutrition chronic kidney disease cardiovascular disease Pediatrics

Latest news

Tag

Ivermectin for COVID-19: From Pandemic Controversy to Definitive Futility in the REMAP-CAP and Global Randomized Trials

Ivermectin for COVID-19: From Pandemic Controversy to Definitive Futility in the REMAP-CAP and Global Randomized Trials

A comprehensive evidence-based synthesis of the REMAP-CAP trial and major international RCTs, demonstrating that ivermectin fails to improve clinical outcomes, survival, or organ support requirements in hospitalized and non-hospitalized COV

Section: Clinical UpdatesMay 12, 2026

Community-Centered Education Improves Clinical Trial Knowledge and Self-Efficacy Among Minoritized Women

Community-Centered Education Improves Clinical Trial Knowledge and Self-Efficacy Among Minoritized Women

A culturally tailored educational intervention significantly improved clinical trial knowledge and self-efficacy among African American and Hispanic women, highlighting the potential of community partnerships to address disparities in gynec

Section: newsApr 27, 2026

Statistical Inconsistency in ALS Trials: How Analysis Methods Skew Treatment Efficacy

Statistical Inconsistency in ALS Trials: How Analysis Methods Skew Treatment Efficacy

A study reveals significant variability in ALSFRS-R analysis methods across 45 ALS trials, impacting treatment effect estimates and increasing false-positive risks, with implications for clinical decision-making and drug development.

Section: NeurologyApr 24, 2026

Adaptive AI Transforms Cardiovascular Event Adjudication: New Algorithm Achieves Near-Human Accuracy Across Multiple Endpoints

Adaptive AI Transforms Cardiovascular Event Adjudication: New Algorithm Achieves Near-Human Accuracy Across Multiple Endpoints

Researchers developed and validated ADAPT-CEC, an artificial intelligence algorithm that can adjudicate cardiovascular events across different trial definitions. A hybrid approach combining AI with selective human review achieved 95.6% accu

Section: AIApr 5, 2026

Long-Term Durability and Clinical Stability of Acoramidis in Transthyretin Amyloid Cardiomyopathy: A 54-Month Synthesis

Long-Term Durability and Clinical Stability of Acoramidis in Transthyretin Amyloid Cardiomyopathy: A 54-Month Synthesis

This review synthesizes the 54-month results of the ATTRibute-CM open-label extension, demonstrating that early and continuous acoramidis treatment provides sustained reductions in mortality and cardiovascular hospitalizations while maintai

Section: CardiologyApr 3, 2026

Beyond the Target: Why SBP Trajectories Predict Functional Recovery in Acute Intracerebral Hemorrhage

Beyond the Target: Why SBP Trajectories Predict Functional Recovery in Acute Intracerebral Hemorrhage

A pooled analysis of 11,269 patients from the INTERACT and ATACH-II trials reveals that 24-hour systolic blood pressure trajectories, rather than just single targets, significantly influence functional outcomes after intracerebral hemorrhag

Section: NeurologyMar 21, 2026

Bridging the Evidence Gap: African Representation in Global Randomized Controlled Trials (2019–2024)

Bridging the Evidence Gap: African Representation in Global Randomized Controlled Trials (2019–2024)

This systematic review analyzes the profound underrepresentation of African populations in high-impact clinical trials, revealing a stark disparity in cardiovascular and general medical research that limits the global applicability of evide

Section: Medical NewsMar 20, 2026

PrimeC Shows Significant Long-term Functional Benefit and Reduced Mortality in ALS: Insights from the PARADIGM Trial

PrimeC Shows Significant Long-term Functional Benefit and Reduced Mortality in ALS: Insights from the PARADIGM Trial

The Phase 2b PARADIGM trial reveals that PrimeC, a novel oral combination therapy, is safe and significantly slows functional decline and reduces the risk of death or hospitalization in ALS patients over 18 months.

Section: NeurologyMar 18, 2026

Optimized Heart Failure Therapy in Advanced Cancer: Insights from the EMPATICC Trial

Optimized Heart Failure Therapy in Advanced Cancer: Insights from the EMPATICC Trial

The EMPATICC trial explored heart failure therapy for patients with advanced cancer in palliative care. While it did not meet its primary endpoint for self-care ability due to high mortality, survivors showed improved cardiac biomarkers and

Section: CardiologyMar 12, 2026

Abbreviated Romosozumab Regimens in Postmenopausal Osteoporosis: A Review of the LIDA Trial and the Shift Toward Precision Anabolic Dosing

Abbreviated Romosozumab Regimens in Postmenopausal Osteoporosis: A Review of the LIDA Trial and the Shift Toward Precision Anabolic Dosing

This review evaluates the LIDA trial’s findings that 3 months of romosozumab followed by denosumab is non-inferior to 12 months of romosozumab, offering a cost-effective strategy to mitigate long-term side effects.

Section: Clinical UpdatesMar 10, 2026

Challenging the ‘More is Better’ Paradigm: Intensive Training Shows No Added Benefit in Recent Spinal Cord Injury

Challenging the ‘More is Better’ Paradigm: Intensive Training Shows No Added Benefit in Recent Spinal Cord Injury

A Phase 3 pragmatic trial found that 12 hours of weekly intensive task-specific training added to usual care does not improve motor recovery in recent spinal cord injury patients, suggesting a potential plateau in the benefits of early reha

Section: NeurologyMar 9, 2026

Low-Dose Lithium for Mild Cognitive Impairment: A Pilot Randomized Clinical Trial and Synthesis of Emerging Neuroprotective Paradigms

Low-Dose Lithium for Mild Cognitive Impairment: A Pilot Randomized Clinical Trial and Synthesis of Emerging Neuroprotective Paradigms

This review evaluates a recent 2-year pilot RCT on low-dose lithium carbonate for MCI, synthesizing its findings with emerging evidence on Aβ clearance, gut-brain axis modulation, and multimodal disease forecasting.

Section: Clinical UpdatesMar 8, 2026

Revisiting Pharmacotherapy in Nonobstructive Hypertrophic Cardiomyopathy: Insights from a Randomized Triple-Crossover Trial of Bisoprolol vs. Verapamil

Revisiting Pharmacotherapy in Nonobstructive Hypertrophic Cardiomyopathy: Insights from a Randomized Triple-Crossover Trial of Bisoprolol vs. Verapamil

A pivotal triple-crossover RCT reveals that while bisoprolol reduces exercise capacity and worsens diastolic markers in nonobstructive HCM, verapamil maintains exercise performance and improves myocardial strain.

Section: CardiologyMar 6, 2026

Topical Botanical Solution Cinainu Shows Sustained Efficacy and Safety in Paediatric Alopecia Areata: Insights from the RAAINBOW Trial

Topical Botanical Solution Cinainu Shows Sustained Efficacy and Safety in Paediatric Alopecia Areata: Insights from the RAAINBOW Trial

The RAAINBOW phase II/III trial demonstrates that Cinainu, a topical botanical solution, significantly improves hair regrowth and quality of life in paediatric patients with moderate-to-severe alopecia areata, offering a well-tolerated alte

Section: DermatologyMar 6, 2026

Long-term Efficacy and Safety of Bimekizumab in Moderate-to-Severe Hidradenitis Suppurativa: A 2-Year Synthesis of the BE HEARD Clinical Program

Long-term Efficacy and Safety of Bimekizumab in Moderate-to-Severe Hidradenitis Suppurativa: A 2-Year Synthesis of the BE HEARD Clinical Program

This review synthesizes 2-year results from the BE HEARD phase 3 trials and their extension, demonstrating that dual IL-17A/F inhibition with bimekizumab provides deep, durable clinical responses and a favorable safety profile for patients

Section: Clinical UpdatesMar 6, 2026

SGLT2 Inhibition and Atrial Fibrillation Recurrence Post-Ablation: Insights from the DARE-AF Randomized Clinical Trial

SGLT2 Inhibition and Atrial Fibrillation Recurrence Post-Ablation: Insights from the DARE-AF Randomized Clinical Trial

The DARE-AF trial demonstrates that 10 mg of dapagliflozin for three months does not significantly reduce early arrhythmia recurrence or AF burden following catheter ablation in patients without existing indications for SGLT2 inhibitors.

Section: CardiologyMar 3, 2026

Percutaneous Coronary Intervention Before TAVR: A Nationwide Synthesis of Clinical Outcomes and Bleeding Risks

Percutaneous Coronary Intervention Before TAVR: A Nationwide Synthesis of Clinical Outcomes and Bleeding Risks

A nationwide Swedish registry analysis demonstrates that routine PCI before TAVR for significant coronary artery disease does not improve survival or reduce urgent revascularization, but significantly increases bleeding risk while reducing

Section: CardiologyMar 2, 2026

Optimizing Pediatric Outcomes: Evidence-Based Advancements in Respiratory Delivery, Neonatal Support, and Precision Therapeutics

Optimizing Pediatric Outcomes: Evidence-Based Advancements in Respiratory Delivery, Neonatal Support, and Precision Therapeutics

This review synthesizes practice-changing pediatric research, highlighting how device selection in acute wheezing, automated oxygen titration in neonates, and novel siRNA therapies for hypercholesterolemia are redefining clinical standards

Section: Clinical UpdatesMar 2, 2026

Ensitrelvir Demonstrates Potent Antiviral Efficacy Comparable to Nirmatrelvir in Early COVID-19: Insights from the PLATCOV Trial

Ensitrelvir Demonstrates Potent Antiviral Efficacy Comparable to Nirmatrelvir in Early COVID-19: Insights from the PLATCOV Trial

The PLATCOV trial identifies ensitrelvir as a highly effective oral antiviral, achieving rapid SARS-CoV-2 clearance comparable to ritonavir-boosted nirmatrelvir. This phase 2 adaptive trial suggests ensitrelvir is a viable alternative for o

Section: Infectious DiseasesMar 2, 2026

Metformin Fails to Improve Walking Performance in Peripheral Artery Disease: Results of the PERMET Randomized Trial

Metformin Fails to Improve Walking Performance in Peripheral Artery Disease: Results of the PERMET Randomized Trial

The PERMET randomized clinical trial found that metformin did not improve the 6-minute walk distance or secondary walking outcomes in patients with peripheral artery disease without diabetes, suggesting no benefit for functional impairment

Section: CardiologyFeb 24, 2026

Prev 1 2 3 5 Next